1705 Amended schedule of therapeutic medications  

  • STATE HORSE RACING COMMISSION

    Amended Schedule of Therapeutic Medications

    [46 Pa.B. 6204]
    [Saturday, October 1, 2016]

     The State Horse Racing Commission (Commission), in accordance with the authority in section 2812-D(6) of The Administrative Code of 1929 (71 P.S. § 720.32(6)) and more specifically 58 Pa. Code § 163.304 (relating to substances of therapeutic value), adopts the Amended Schedule of Therapeutic Medications (Schedule) established by the Nationally-recognized Racing Medication and Testing Consortium (RMTC) and adopted by the Association of Racing Commissioners International (ARCI).

     Under 58 Pa. Code § 163.304, the Commission may approve and adopt by reference the RMTC/ARCI schedule of therapeutic medications and their respective threshold levels for use in the thoroughbred horse racing sector of the racing industry. On July 27, 2016, the Commission formally approved the amended Schedule as follows. On December 15, 2013, the Commission previously approved and published at 43 Pa.B. 7612 (December 28, 2013) the original RMTC Schedule. The amended Schedule has been posted and published on the Commission's web site. As the RMTC/ARCI continues to research testing methodologies, therapeutic medications and their various thresholds, the Commission will thereafter publish the amendments or additions, or both.

     The Commission did not adopt any withdrawal times related to the enumerated therapeutic medications and the threshold levels. The information on the Schedule does not constitute a guarantee, warranty or assurance that the use of any therapeutic medications at the dosages listed will not result in a positive-race test. Owners, trainers or any other persons responsible for the care, custody and control of a racehorse are strongly encouraged to seek the advice of their respective Veterinarians regarding the use of therapeutic medications.

    RMTC

    Controlled Therapeutic Medications

    Substance Threshold Route of Administration Experimental
    Administration Dosage
    Acepromazine HEPS—10 ng/mL of urine Intravenous 0.05 mg/kg
    Albuterol 1 ng/mL of urine Intra-nasal1
    720 mcg total dose

    Betamethasone 10 pg/mL in plasma or
    serum
    lntra-articular as
    betamethasone acetate and betamethasone sodium
    phosphate
    9 mg total in one articular space
    Butorphanol Free butorphanol—2 ng/mL of plasma, or Total butorphanol—
    300 ng/mL of urine
    Intravenous 0.1 mg/kg
    Cetirizine 6 ng/mL of plasma/serum Orally 0.4 mg/kg twice daily for five doses
    Cimetidine 400 ng/mL of plasma or serum Orally 20 mg/kg twice daily for seven doses
    Clenbuterol 140 pg/mL of urine or LOD in plasma Orally 0.8 mcg/kg
    Dantrolene 5-OH dantrolene—0.1 ng/mL
    of plasma or serum
    Orally 500 mg total dose
    Detomidine 1 ng/mL in plasma or serum,
    2 ng/mL of carboxydetomidine
    in urine
    Intravenous 5 mg/kg
    Dexamethasone 5 pg/mL of plasma or serum Oral, Intravenous,
    intramuscular
    0.05 mg/kg
    Diclofenac 5 ng/mL of plasma or serum Systemic 5" ribbon of Surpass every 12 hours to one site
    DMSO 10 mcg/mL of plasma or serum Topical Up to 2 ounces
    Firocoxib 20 ng/mL of plasma or serum Orally 0.1 mg/kg for 4 days
    Flunixin 20 ng/mL of plasma or serum Intravenous 1.1 mg/kg
    Furosemide 100 ng/mL in blood and urine specific gravity < 1.010 Intravenous 500 mg total dose
    Glycopyrrolate 3 pg/mL of plasma or serum Intravenous 1 mg total dose
    Guaifenesin 12 ng/mL of plasma or serum Orally 2 g twice daily for five doses
    Isoflupredone 100 pg/mL of serum or plasma Subcutaneous or Intra-articular administration of isoflupredone acetate 10 mg total dose subcutaneous or 20 mg total dose in one articular space
    Ketoprofen 10 ng/mL of plasma or serum Intravenous 2.2 mg/kg
    Lidocaine 20 pg/mL of total 30H-lidocaine in plasma Subcutaneous 200 mg of total dose
    Mepivacaine 3-OH-mepivacaine—10 ng/mL
    in urine or mepivacaine at
    LOD in plasma or serum
    Subcutaneous—distal limb 0.07 mg/kg
    Methocarbamol 1 ng/mL of plasma or serum Intravenous2
    15 mg/kg IV, 5 g oral

    Methylprednisolone 100 pg/mL in plasma or serum Intra-articular as methylprednisolone acetate 100 mg total in one articular space3
    Omeprazole Omeprazole sulfide—10 ng/mL
    in serum/plasma
    Orally 2.2 grams once daily for 4 days
    Phenylbutazone 2 mcg/mL of plasma or serum Intravenous 4.0 mg/kg
    Prednisolone 1 ng/mL of plasma or serum Orally 1 mg/kg
    Procaine penicillin4
    25 ng/mL of plasma Intra-muscular 17 mg/kg

    Ranitidine 40 ng/mL of plasma or serum Orally 8 mg/kg twice daily for seven doses
    Triamcinolone acetonide 100 pg/mL of plasma or serum Intra-muscular 9 mg total in one articular space
    Xylazine 0.01 ng/mL of plasma Intravenous 200 mg

    THOMAS F. CHUCKAS, Jr., 
    Director
    Bureau of Thoroughbred Horse Racing

    _______

Document Information